European Hematology Association Congress | Conference

Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM
July 14, 2021

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma
July 06, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study
June 29, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

Shaji Kumar, MD on the Impact of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed MM
June 24, 2021

Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.

Improved OS Seen With Momelotinib-Associated Transfusion Independence at 24 Weeks in Myelofibrosis
June 21, 2021

Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.

Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM
June 19, 2021

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma
June 16, 2021

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
June 16, 2021

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Daratumumab Plus CyBorD Followed by Daratumumab Maintenance Achieves Deep Responses for Multiple Myeloma
June 16, 2021

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.

Maintenance With Rituximab for MCL Prolongs Time to Next Treatment
June 15, 2021

Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.